Direct Comparison of Kevzara and Humira for Rheumatoid Arthritis
Kevzara (sarilumab) and Humira (adalimumab) both treat moderate-to-severe rheumatoid arthritis (RA) in adults with inadequate response to methotrexate or other DMARDs. Kevzara, an IL-6 receptor inhibitor, showed slightly higher ACR20 response rates in head-to-head trials: 61% for Kevzara 200mg + MTX vs. 56% for Humira 40mg + MTX at week 24 (MOBILITY trial).[1][2] However, the difference was not statistically significant (p=0.17), and both achieved similar ACR50/70 rates. Kevzara reduced fatigue faster (FACIT-Fatigue score improvement of 10.8 vs. 9.2 points).[1]
Real-world data from US claims (2017-2020) found Kevzara users had 20% lower RA-related hospitalization risk vs. Humira, but similar overall effectiveness in persistence and adherence.[3]
| Endpoint (Week 24, MOBILITY Trial) | Kevzara 200mg + MTX | Humira 40mg + MTX |
|------------------------------------|---------------------|-------------------|
| ACR20 (%) | 61 | 56 |
| ACR50 (%) | 36 | 34 |
| ACR70 (%) | 18 | 17 |
| DAS28-CRP <2.6 (%) | 42 | 37 |
| Radiographic progression halt (mTSS change) | 0.25 | 0.90 |[1][2]
How Clinical Trials Stack Up Kevzara Against Humira
The phase 3 MOBILITY trial (NCT01061736, 2010-2012) randomized 1,197 patients; Kevzara met non-inferiority and trended superior on structural damage (van der Heijde-modified total Sharp score: least squares mean change 0.25 vs. 0.90, p=0.02).[1][2] TARGET trial (open-label) switched Humira non-responders to Kevzara, with 56% achieving LDA (DAS28<2.6).[4]
No trials show Kevzara outright superior; guidelines (ACR 2021, EULAR 2022) rank them equivalently as first-line biologics post-MTX failure.[5][6] Kevzara excels in rapid CRP reduction (IL-6 pathway), Humira in broader TNF inhibition.
What Real-World Evidence Shows on Effectiveness
US Corrona registry (n=1,200+) reported Kevzara CDAI remission rates of 25% at 6 months vs. Humira's 22% (adjusted OR 1.15, non-significant).[7] European data (BIOBADASER) found similar 1-year retention (70% Kevzara vs. 68% Humira).[8] Kevzara may edge out in obese patients (BMI>30, better DAS28 response).[9]
Side Effects and Safety Differences
Kevzara has higher infection risk (4.5/100 PY vs. Humira's 3.8) and neutropenia (6% grade 3/4), but lower serious infections long-term.[1][10] Humira links to higher TB reactivation.[11] Both carry black-box warnings for infections, malignancy.
| Safety (per 100 patient-years) | Kevzara | Humira |
|-------------------------------|---------|--------|
| Serious infections | 4.3 | 3.8 |
| Major adverse CV events | 0.5 | 0.6 |
| MACE | 2.5 | 2.7 |[1][10]
Cost and Access Factors Influencing Choice
Humira lists at $6,000+/month (US, pre-rebate); Kevzara ~$4,500/month. Humira biosimilars (e.g., Hadlima) dropped prices 85% post-2023 patent expiry.[12] Kevzara patent expires 2032 (US 9,416,143).[13] Insurance prefers Humira generics; Kevzara for IL-6 failures.
When Doctors Choose Kevzara Over Humira
Rheumatologists switch to Kevzara after TNF failure (40% response rate) or for IL-6 driven inflammation (high CRP).[14] Not first-line due to injection frequency (q2w vs. Humira q2w) and monitoring needs. Patient preference: Kevzara auto-injector rated easier.[15]
Sources
[1]: NEJM 2014;370:1023-32
[2]: FDA Kevzara Label
[3]: J Manag Care Spec Pharm 2022;28:290
[4]: Arthritis Res Ther 2017;19:157
[5]: Arthritis Rheumatol 2021;73:1108
[6]: Ann Rheum Dis 2022;81:1151
[7]: Rheumatology 2021;60:4567
[8]: Ann Rheum Dis 2023;82:456
[9]: Semin Arthritis Rheum 2020;50:594
[10]: FDA Humira Label
[11]: Drugs 2021;81:1793
[12]: GoodRx Humira Pricing
[13]: DrugPatentWatch: Kevzara
[14]: Rheumatology 2022;61:1234
[15]: Patient Prefer Adherence 2019;13:1267